Zacks Investment Research Lowers Citius Pharmaceuticals (NASDAQ:CTXR) to Sell
According to Zacks, “Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care and prescription products. Citius Pharmaceuticals, Inc. is headquartered in Cranford, New Jersey. “
Separately, Dawson James assumed coverage on Citius Pharmaceuticals in a research note on Friday, September 6th. They issued a buy rating and a $7.00 price objective for the company.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Vanguard Group Inc. grew its position in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 453,156 shares of the company’s stock after purchasing an additional 342,180 shares during the period. Vanguard Group Inc. owned about 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent quarter. 2.83% of the stock is currently owned by institutional investors.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Recommended Story: How dollar cost averaging works
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.